Protagonist soars on Janssen IBD deal

Oral peptide therapeutic company Protagonist Therapeutics Inc. (NASDAQ:PTGX) jumped $3.60 (44%) to $11.82 on Tuesday after it granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) exclusive,

Read the full 292 word article

How to gain access

Continue reading with a
two-week free trial.